Merck Pressured to Halt Gardasil Vaccine Lobbying

Health and Healthcare

Published: February 22, 2007 1:23 am

By H.S. Ayoub
BioHealth Investor.com

I wrote earlier about the anti-vaccination movement, and how Merck (MRK) has been receiving a lot of backlash because of its lobbying efforts.

Merck (MRK) has been lobbying pretty hard for mandating the vaccination of pre-teen girls with its HPV vaccine Gardasil.

More than 20 states have drafted bills to mandate the vaccination, and in fact, an executive order was made by Texas Gov. Rick Perry to force young girls to be vaccinated. Mr. Perry’s executive order calls for all girls entering sixth grade in that state to be vaccinated by September 2008.

Public backlash against the mandate, including parent groups, has forced Merck to end its lobbying campaign. Among the main arguments made by the opposition included, the freedom to make that decision for their daughters on their own, and of course, the high cost. A three dose regimen of Gardasil costs $360, higher than most mandated vaccination programs.

Merck will now focus on programs aimed at educating the public about HPV, which is a virus that is sexually transmitted, and is a cause of cervical cancer.

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.